Project Grant SB1CA302068
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jupiter, FL 33458, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Mayo Clinic Jacksonville (a nonprofit corporation registered as Scott Lynch MD) to develop a first-in-class non-muscle myosin II (NMII) inhibitor, MT-125, for the treatment of glioblastoma. The $607,634 award, effective January 1, 2025 through December 31, 2029, supports research to uncover the mechanisms behind the synergistic effects of MT-125 when combined with...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $1,102,729 to Vortex Therapeutics Inc. to develop a novel small molecule inhibitor of the MYC oncoprotein for cancer therapy. The project aims to advance this lead compound, named MYCI606, which has demonstrated potent anti-tumor efficacy in preclinical models of prostate, liver, and other MYC-driven cancer types. The award period runs from September 2025 through August...
- This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $451,996 to the University of Texas at Arlington (UTA) to develop high-throughput screening platforms for identifying and validating drugs that can target migrating and treatment-resistant glioblastoma (GBM) cancer cells. The overarching goal is to transform GBM, which is currently a fatal disease, into a more localized condition that can be effectively treated through surgery and/or...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,820,337.00 to the Regents of the University of Michigan to develop new methods to directly measure metabolic pathway activity in mouse models and patients with glioblastomas (GBMs), which are deadly and incurable brain cancers. The goal is to identify optimal metabolic treatment strategies for GBM patients by evaluating the safety, on-target activity, and potential efficacy of new...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...
- This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...
- This $3,155,815 Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, supports research to develop advanced magnetic resonance imaging techniques for non-invasive measurement of glutamate metabolism in glioblastoma brain tumors. The primary awardee is Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, which will leverage its expertise in medical research, imaging technologies, and...